Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)

Figures & data

Table 1. Demographic characteristics at baseline of patients treated with tildrakizumab 100 and 200 mg.

	Tildrakizumab 200 mg	Tildrakizumab 100 mg	p-value
Mean (SD)
Age, years	52.90 (13.38)	54.38 (15.19)	0.319
Body weight, kg	91.09 (18.87)	79.95 (17.09)	< 0.001
BMI, kg/m^2	30.43 (5.87)	26.95 (5.37)	< 0.001
N (%)
Male	88 (65.7)	242 (66.5)	0.865
PsA	13 (9.7)	49 (13.5)	0.26
Bio-Naïve	48 (35.8)	131 (36)	0.623
At least one difficult-to-treat areas	99 (73.9)	188 (51.7)	< 0.001

PASI: Psoriasis Area and Severity Index; BMI: Body Mass Index; PsA: Psoriatic Arthritis.

Figure 1. Percentage of patients who achieve PASI 90, PASI 100 and PASI ≤ 2 after 16 weeks of treatment with tildrakizumab 100 and 200 mg.

*p < 0.05; **p < 0.01; ***p < 0.001.

PASI: Psoriasis Area and Severity Index.

Figure 2. Percentage of patients achieving PASI 90, PASI 100, and PASI ≤ 2 according to difficult-to-treat areas, body weight ≥ 90 kg, and PASI ≥ 16.

PASI: Psoriasis Area and Severity Index; ns: not significant; *p < 0.05; **p < 0.01; ***p < 0.001.

Data availability statement

All the patients’ data and information supporting the findings of the study are available from the corresponding author upon reasonable request.